Peptide Schedule
Glucagon (GlucaGen)29 residuesHSQGTFTSDYSKYLDSRRAQDFVQWLMNTEach bubble = one amino acid. Size = residue mass. Color = chemical class.Glucagon (GlucaGen) Dosage Calculator
Glucagon is a naturally occurring 29-amino-acid peptide hormone secreted by the alpha cells of the pancreatic islets of Langerhans.
0.5mcg · Single dose
Summary: Add 0mL BAC water to your 1mg vial. Draw to < 0.1 units on a U-100 syringe for a 0.5mcg dose. This vial will last 0 doses.
Cycle Planner
Glucagon (GlucaGen) Pharmacokinetics
Pharmacokinetics — Active Dose Over Time
t½ = 8-18 minutes (IV), ~26 minutes (IM), ~35-45 minutes (SC/intranasal)Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Glucagon (GlucaGen) Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 0.5mg | Single dose |
| Moderate | 1mg | Single dose |
| Aggressive | 1mg | Single dose |
Note: Glucagon is an FDA-approved emergency treatment for severe hypoglycemia in people with diabetes. It is a 29-amino-acid peptide hormone produced by alpha cells of the pancreatic islets of Langerhans. Unlike most peptides used in research or optimization contexts, glucagon is strictly an emergency rescue medication. It is available as a lyophilized powder for reconstitution (GlucaGen, Glucagon Emergency Kit), a ready-to-use liquid autoinjector (Gvoke), and an intranasal dry powder (Baqsimi). Each formulation is designed for rapid deployment during hypoglycemic emergencies when the patient is unable to consume oral carbohydrates. Reconstituted glucagon should be used immediately and never stored for later use. The 1 mg dose is standard for adults and children over 25 kg; a 0.5 mg dose is recommended for pediatric patients under 25 kg.
About Glucagon (GlucaGen)
Glucagon is a naturally occurring 29-amino-acid peptide hormone secreted by the alpha cells of the pancreatic islets of Langerhans. It serves as the primary counter-regulatory hormone to insulin, playing a critical role in glucose homeostasis by raising blood glucose levels when they fall dangerously low. Glucagon was first crystallized by Staub in 1955 and has been used clinically for decades as the standard emergency treatment for severe hypoglycemia. The recombinant DNA-derived form, marketed as GlucaGen by Novo Nordisk and as the Glucagon Emergency Kit by Eli Lilly, received FDA approval for the treatment of severe hypoglycemia. More recently, Eli Lilly introduced Baqsimi, the first nasally administered glucagon approved by the FDA in 2019, providing a needle-free alternative for emergency hypoglycemia rescue. Xeris Pharmaceuticals also launched Gvoke, a room-temperature-stable, ready-to-use liquid glucagon in prefilled syringe and autoinjector formats. Glucagon acts primarily on the liver, where it binds to the glucagon receptor (GCGR), a G protein-coupled receptor, triggering a cascade that activates adenylyl cyclase, increases intracellular cyclic AMP (cAMP), and activates protein kinase A (PKA). This stimulates glycogenolysis — the breakdown of glycogen into glucose — and enhances gluconeogenesis, the de novo synthesis of glucose from non-carbohydrate precursors. The net result is a rapid and significant increase in blood glucose concentration, typically restoring consciousness within 10 to 15 minutes of administration. Beyond hypoglycemia rescue, glucagon is also FDA-approved as a diagnostic aid during radiologic examination of the gastrointestinal tract, where it is used to temporarily inhibit GI motility. Its safety profile is well-established, with nausea and vomiting being the most common adverse effects. Glucagon remains an essential component of diabetes emergency preparedness, and newer formulations have significantly improved usability for caregivers and first responders.